Topic Biogen Idec

News Biogen Idec

• Biogen Idec and Swedish Orphan Biovitrum receive opinion from EMA on pediatric plan for long-lasting hemophilia B therapy

  Biogen Idec and Swedish Orphan Biovitrum announced that the European Medicines Agency's (EMA) Pediatric Committee (PDCO) has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc).In accordance with th more

• DPZ Signs License Agreement with Biogen Idec

  The German Primate Center (DPZ) and its technology transfer partner Ascenion announced the signing of a license agreement providing Biogen Idec with exclusive, worldwide rights to a patent portfolio directed to a recombinant virus-like particle (VLP) containing VP1 protein for the detection of antib more

• Knopp Neurosciences Forms New Parent Company to Expand Operations and Mission

  Knopp Neurosciences Inc. announced that it has formed a new parent entity called Knopp Biosciences LLC to expand operations with the goal of becoming a more broadly integrated biopharmaceutical company. The corporate restructuring follows an August 2010 agreement under which Biogen Idec secured exc more

Publications Biogen Idec

• Ligand Binding Assays in the 21st Century Laboratory: Platforms

  Ligand Binding Assays in the 21st Century Laboratory: Platforms Content Type Journal Article Category Commentary Pages 1-6 DOI 10.1208/s12248-012-9321-1 Authors Franklin P. Spriggs, Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., 1 Burtt Road, MS G2002, Andover, more

• Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy

  Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy Nature Reviews Drug Discovery 10, 404 (2011). doi:10.1038/nrd3465 Biogen Idec have announced that their fumaric acid ester, dimethyl fumarate (BG-12), has met the primary and secondary end points of a g more

• Biogen Idec restructures, sharpens neurology focus

  Biogen Idec restructures, sharpens neurology focus Nature Biotechnology 29, 7 (2011). doi:10.1038/nbt0111-7 Author: Peter Mitchell more

Market studies Biogen Idec

• South Korea Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: While South Korea's research and development (R&D) environment may be attractive to investors, its pharmaceutical market environment is rather uncertain given the dispute between pharmaceutical companies and the government over pharmaceutical price cuts. We hold to our view that, if the go more

• Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Multiple Sclerosis market. The report identifies more

• Amorfix Life Sciences Ltd. (AMF) - Product Pipeline Analysis

  Amorfix Life Sciences Ltd. (AMF) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Amorfix Life Sciences Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indic more

Websites Biogen Idec